CONTACT US   |  (864) 397-5101

PitchRounds at AdvanSE 2022 Presenting Companies include Rymedi, GlycoPath, Aravis Biotech, Annoviant, Heartbeat Technologies

Five South Carolina organizations are among the chosen to present at AdvanSE’s PitchRounds competition, scheduled for May 25-27 in Atlanta, GA.

Southeast Life Sciences cultivates, convenes, and connects the Southeast entrepreneurial ecosystem to foster life science innovation in promising companies throughout the region from investors across the country. Chosen for 2022 from South Carolina are Rymedi, GlycoPath, Aravis Biotech, Annoviant, and Heartbeat Technologies.

Our investor colleagues count on us to present to them the highest potential life science investments the southeastern United States has to offer. 

“By attending AdvanSE, I get to meet some of the leading entrepreneurs and interesting companies in the Southeast.  AdvanSE offers exclusive opportunities to network with other investors and strategics and is the one-stop shop for innovation in the region.” – Kyp Sirinakis, Co-Founder and Managing Partner, Epidarex Capital

Thanks to the focused, dedicated work of our selection committee, we proudly share with you the roster of PitchRounds at #AdvanSE2022 presenting companies. New for the 2022 edition, Keiretsu Forum’s Mid-Atlantic and South-East regions have committed to providing pitch opportunities to both regions for the winners of the PitchRounds competition.

These companies represent the southeastern United States’ most promising innovative life science companies – from startups seeking milestone-based funding at six figure levels from venture capital firms, corporate venture arms, family offices, and angel groups to more mature companies with institutional investors on board seeking future rounds at $1MM to $15MM plus.

Meet all of the PitchRounds at AdvanSE2022 Presenting Companies here:  click for full story.

Join now to enjoy expanded member benefits!

Enjoy exclusive member content, special events, savings, networking and more

Tamia Sumpter

Tamia is a driven senior undergraduate Bioengineering student currently enrolled at Clemson University. With a strong foundation in her field, she has honed her skills through hands-on experience in research and development at Eli Lilly & Company. During her time in the ADME department, Tamia contributed significantly by working on siRNAs and their applications in finding In Vitro-In Vivo Correlation (IVIVC). Looking ahead, Tamia has set her sights on a promising career in law. She aspires to specialize in Intellectual Property Law, with a particular focus on serving as in-house counsel for leading medical device or pharmaceutical companies. Her enthusiasm for this role is palpable as she prepares to embark on her legal journey! She is also a proud member of the Omicron Phi chapter of Delta Sigma Theta Sorority, Inc., PEER Mentor for Clemson PEER/WiSE, and currently serves as the President of Clemson Bioengineering Organization (CBO). With her unique blend of scientific knowledge and legal interests, Tamia is poised to make a meaningful impact in the healthcare and life sciences industries.